Last reviewed · How we verify
Habitual medication
This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine.
This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine. Used for Attention deficit hyperactivity disorder (ADHD), Major depressive disorder.
At a glance
| Generic name | Habitual medication |
|---|---|
| Also known as | A |
| Sponsor | Hospital Universitario de Canarias |
| Drug class | Norepinephrine-dopamine reuptake inhibitor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By blocking the reuptake of these neurotransmitters, it increases their availability in the synaptic cleft, thereby enhancing their effects on the central nervous system. This leads to increased alertness, energy, and mood improvement.
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
- Major depressive disorder
Common side effects
- Increased heart rate
- Insomnia
- Nausea
- Headache
Key clinical trials
- Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) (NA)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription (NA)
- Investigation of the Relationship Between Periodontitis and Sleep Quality
- Interdisciplinary Program to Improve Lifestyle in Chronic Pathology: Alt Pirineu Aran in Fit (APA-FIT) (NA)
- Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study
- Motor Training in PD (NA)
- Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |